Madagascar vs Tonga: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Madagascar
0.6%
in 2024
Tonga
0.6%
in 2024
Madagascar rank
50th
Tonga rank
50th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Madagascar
- Tonga
How they compare
Madagascar currently reports 0.6% against 0.6% in Tonga, a difference of 0.0%.
Across all 10 years both countries report, Tonga has been ahead every year.
Madagascar ranks 50th and Tonga ranks 50th of 215 countries.
Tonga has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Madagascar | Tonga | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.6% | 1.1% | 0.4% | Tonga |
| 2020s | 0.5% | 0.7% | 0.2% | Tonga |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Madagascar or Tonga?
- Madagascar, at 0.6% against 0.6% in Tonga as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Madagascar and Tonga?
- 0.0%, with Madagascar ahead.
- How many years of comparable data are there for Madagascar and Tonga?
- 10 years are reported by both, from 2015 to 2024.
- How do Madagascar and Tonga rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Madagascar ranks 50th and Tonga ranks 50th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.